ARID2: A new tumor suppressor gene in hepatocellular carcinoma
Oncotarget2011Vol. 2(11), pp. 886–891
Citations Over Time
Hong Zhao, Jian Wang, Yongqing Han, Zhen Huang, Jianming Ying, Xinyu Bi, Jianjun Zhao, Yi Fang, Haitao Zhou, Jianguo Zhou, Zhiyu Li, Yefan Zhang, Xue Yang, Tao Yan, Linfang Wang, Michael Torbenson, Jianqiang Cai
Abstract
Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide, however, genetic-environmental interactions and mechanisms associated with the development of HCC remains largely unclear. Our recent work described novel inactivating mutations of ARID2 (AT-rich interactive domain 2) in four major subtypes of HCC through exomic sequencing of ten HCV-associated HCCs and subsequent evaluation of the tumors from additional affected individuals. Here, we summarize the current knowledge about the relevance of ARID2 in HCC and the implication in future patient care.
Related Papers
- Clinicopathologic features and risk factors for hepatocellular carcinoma: results from a single center in southern Turkey.(2003)
- Spontaneous rupture of hepatocellular carcinoma.(2002)
- Pathology of hepatocellular carcinoma(2006)
- The medical management of hepatocellular carcinoma (HCC) in Japan: a review with implications for HCC seen in the west.(1997)
- → Improving prognosis of patients with very early hepatocellular carcinoma: How far are we going?(2020)1 cited